published meta-analysis   sensitivity analysis   studies

azithromycin plus hydroxychloroquine in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24] ProPAC-COVID, 2021 0.08 [0.00; 8.65] 0.56[0.17; 1.87]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, ProPAC-COVID, 202120%462moderatenot evaluable deaths (time to event analysis only)detailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24] 0.64[0.18; 2.24]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%345NAnot evaluable clinical deteriorationdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.99 [0.57; 1.72] 0.99[0.57; 1.72]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%444NAnot evaluable clinical improvementdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.81 [0.54; 1.22] 0.81[0.54; 1.22]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%444NAnot evaluable clinical improvement (14-day)detailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.01 [0.58; 1.76] 1.01[0.58; 1.76]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%444NAnot evaluable mechanical ventilationdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.77 [0.81; 3.87] 1.77[0.81; 3.87]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%345NAnot evaluable ICU admissiondetailed resultsProPAC-COVID, 2021 1.24 [0.26; 5.80] 1.24[0.26; 5.80]ProPAC-COVID, 202110%117NAnot evaluable serious adverse eventsdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.87 [0.36; 9.75] 1.87[0.36; 9.75]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%416NAnot evaluable acute kidney injury detailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.18 [0.44; 3.18] 1.18[0.44; 3.18]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%345NAnot evaluable adverse eventsdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.22 [1.43; 3.44] 2.22[1.43; 3.44]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%416NAnot evaluable arrhythmiadetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.24 [0.23; 21.69] 2.24[0.23; 21.69]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%416NAnot evaluable elevated liver enzymesdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 3.48 [1.40; 8.64] 3.48[1.40; 8.64]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%416NAnot evaluable long QTdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 9.79 [1.27; 75.50] 9.79[1.27; 75.50]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%174NAnot evaluable Thromboembolic eventsdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.89 [0.31; 2.55] 0.89[0.31; 2.55]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%345NAnot evaluable0.220.01.0relative treatment effectwww.metaEvidence.org2024-03-28 20:47 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 889 - roots T: 290